A
AnaBios
Generates highly valuable, predictive human data in advance of clinical trials, ensuring the selection of the most effective and safest drugs, thereby reducing the time and expense related to clinical…
About AnaBios
AnaBios operates as a Contract Research Organization (CRO) specializing in human-focused drug discovery. The company provides human tissue samples and advanced translational technologies to pharmaceutical firms and biotech companies. These services are crucial at every stage of drug discovery, from preclinical trials to the development of novel therapeutics. AnaBios leverages predictive human data to enhance the safety and efficacy of new drugs, thereby reducing product development costs and shortening the time to market. The company primarily serves clients in the pharmaceutical and biotechnology sectors, offering a business model based on service fees for providing human tissue samples and related research services. AnaBios generates revenue by partnering with top pharmaceutical firms, utilizing its proprietary technologies to deliver actionable human data that accelerates drug development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- San Diego, United States
- Employees
- 41
- Open positions
- 1
- Dealroom signal
- 84.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Data Analytics, Predictive Analytics, Biotechnology, Clinical, Medical Data, Tech for Biotech and Pharma, Hard Tech
- Technology
- Big Data, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Apr 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning AnaBios.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Jun 2022 | $6.5M | — | Undisclosed | ↗ |
| EARLY VCEquity / VC | Dec 2019 | $1.1M | $4.5M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AnaBios is 3.9K monthly website visits, up 14.7% over the last three months. AnaBios's team grew 13.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Tech Coast Angels
Rady Venture Fund
XYence
Other known investors2 additional known investors
Keiretsu Forum
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AnaBios on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AnaBios’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.